Cell line · CVCL_2176
Papers35
1 to 20 of 35
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PAX3::FOXO1-Targeting PROTAC Induces Myogenic Differentiation of Fusion-Positive Rhabdomyosarcoma Cells. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| High-Risk Rhabdomyosarcomas Feature a Convergent Cell State. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Therapeutic targeting of YOD1 disrupts the PAX-FOXO1/N-Myc feedback loop in rhabdomyosarcoma. | JCI Insight | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The PIK3CA/AKT pathway drives therapy resistance in rhabdomyosarcoma. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PAX3-FOXO1 Drives Targetable Cell State-Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas. | Cancer Immunol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma. | J Hematol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models. | Clin Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance. | Sci Adv | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models. | Mol Cancer Ther | 2022 | Its Methods give the RRID and name the line | PubMed | |
| FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas. | Mol Oncol | 2022 | Its Methods give the RRID and name the line | PubMed | |
| A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy. | Cancer Gene Ther | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Assessing alveolar rhabdomyosarcoma cell lines as tumor models by comparison of mRNA expression profiles. | Gene | 2020 | Cellosaurus cites it | PubMed | |
| Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Cell | 2020 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_2176/papers